Literature DB >> 6245145

Antibiotics in the treatment of gastroenteritis caused by enteropathogenic Escherichia coli.

A Thorén, T Wolde-Mariam, G Stintzing, T Wadström, D Habte.   

Abstract

The role of antibiotics in treating endemic infantile diarrhea caused by enteropathogenic Escherichia coli has not been determined. In a controlled study of 49 patients, one group received mecillinam and another group received trimethoprim-sulfamethoxazole. A third group served as control subjects. Serotype O111:B4 dominated. Treatment, as evaluated clinically on the third day, resulted in cure for 79% of those receiving mecillinam, 73% of those receiving trimethoprim-sulfamethoxazole, and 7% of the control subjects. Bacteriologic cure was confirmed in 53%, 53%, and 0, respectively. The statistically significant difference between antibiotic-treated patients and control subjects (P less than 0.001) indicated that antibiotics are an important supplement in the treatment of endemic severe diarrhea caused by enteropathogenic E. coli.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245145     DOI: 10.1093/infdis/141.1.27

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  4 in total

1.  Enteropathogenic Escherichia coli diarrhea in hospitalized children at Delhi.

Authors:  P Aggarwal; M Singh
Journal:  Indian J Pediatr       Date:  1987 Nov-Dec       Impact factor: 1.967

2.  Role of a novel antidiarrheal agent, BW942C, alone or in combination with trimethoprim-sulfamethoxazole in the treatment of traveler's diarrhea.

Authors:  C D Ericsson; P C Johnson; H L DuPont; D R Morgan
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

3.  Enteropathogenic Escherichia coli and life threatening chronic diarrhoea.

Authors:  S M Hill; A D Phillips; J A Walker-Smith
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

Review 4.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.